ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Geographical trends of drug-resistant strains of Mycobacterium leprae in TLM hospitals: insights from a four-year study across eleven hospitals in eight Indian States.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeprosy, caused by Mycobacterium leprae, remains a significant global health concern despite the introduction of the WHO-recommended Multidrug Therapy (MDT). Recent reports of antimicrobial resistance (AMR) to key anti-leprosy drugs, including rifampicin, dapsone, and ofloxacin, have raised concerns about treatment efficacy and disease control.
objectiveThis study aimed to investigate the geographical distribution of drug-resistant M. leprae strains among leprosy patients in India, including new, reactional, defaulter, and relapse cases, from 2021 to 2025.
methodsA cross-sectional study was conducted at 11 hospitals of The Leprosy Mission Trust India (TLMTI) across 8 states of India. Slit-skin smears and biopsies were collected from 3,030 confirmed leprosy cases. DNA was extracted and screened for mutations in the rpoB, folP1, and gyrA genes using PCR and Sanger sequencing, in accordance with WHO guidelines.
resultsWe observed overall drug resistance to rifampicin (7.8%), dapsone (5.9%), and ofloxacin (7.0%) in the study. Multidrug resistance was observed in 2.1% of cases. Rifampicin resistance was identified in 11.6% of relapse cases (84/715), 13.8% of defaulter cases (26/188), 7.3% of T2R cases (84/1148), 10.4% of T1R cases (26/249), and 2.4% of newly diagnosed cases (18/730). Rifampicin-resistant strains were observed to be geographically clustered in the districts of Prayagraj, Bokaro, Purulia, and Champa.
conclusionThe detection of primary and secondary drug resistance in new and relapse cases highlights the ongoing transmission of drug- resistant M. leprae strains and challenges to effective case management. These findings highlight the urgent need for expanded AMR surveillance, routine molecular diagnostics, and reinforced adherence to MDT to curb the spread of resistant strains and support India’s leprosy elimination goals.
Indexed as
Identifiers
41432848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.